Bales pleaded guilty in June in a deal to avoid the death penalty for the March 11, 2012, massacre. His sentencing begins today with the selection of military jurors whose only task will be to determine whether he is sentenced to life with the possibility of parole, or without it.
Army prosecutors have flown in nine Afghan villagers to testify at the hearing, which is expected to last about a week.
The villagers, some of whom have expressed outrage that Bales is going to escape the death penalty, have not encountered him in person since the attack, nor have they heard him apologise. Bales, who told a judge at his plea hearing that he couldn't explain why he committed the killings, did not say then that he was sorry, but his lawyers hinted that an apology might be forthcoming at his sentencing.
Bales' attorneys have indicated they plan to present evidence that could warrant leniency, including that during at least one of his prior deployments to Iraq, Bales had been prescribed the anti-malaria drug mefloquine, known by its brand name Lariam. Last month, the US Food and Drug Administration issued a new warning that the drug can cause long-term neurological damage and serious psychiatric side effects.
"Our general theme is that Sgt Bales snapped," said John Henry Browne, one of his civilian attorneys. "That's kind of our mantra, and we say that because of all the things we know: the number of deployments, the head injuries, the PTSD, the drugs, the alcohol.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
